| scholarly article | Q13442814 |
| P50 | author | Carol Brayne | Q29642394 |
| Eline M Bunnik | Q56923691 | ||
| Richard Milne | Q59158579 | ||
| P2093 | author name string | Jose-Luis Molinuevo | |
| Craig Ritchie | |||
| Jean Georges | |||
| Karine Fauria | |||
| Edo Richard | |||
| Ana Diaz | |||
| Shirlene Badger | |||
| Dianne Gove | |||
| Katie Wells | |||
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis | Q26765401 | ||
| Behavioural Risk Factors in Mid-Life Associated with Successful Ageing, Disability, Dementia and Frailty in Later Life: A Rapid Systematic Review | Q26769028 | ||
| Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review | Q26786212 | ||
| Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results | Q27345258 | ||
| Communicating mild cognitive impairment diagnoses with and without amyloid imaging | Q33640373 | ||
| The A4 study: stopping AD before symptoms begin? | Q33725775 | ||
| Qualitative research in health care. Assessing quality in qualitative research | Q33807143 | ||
| Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions | Q34135724 | ||
| Public beliefs and knowledge about risk and protective factors for Alzheimer's disease | Q34177996 | ||
| Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. | Q53145536 | ||
| Screening for dementia - is it a no brainer? | Q57529789 | ||
| The emergence of an ethical duty to disclose genetic research results: international perspectives | Q58674081 | ||
| Defeating Alzheimer's disease and other dementias: a priority for European science and society | Q38778638 | ||
| Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary | Q38877710 | ||
| Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. | Q39236470 | ||
| Dementia worry: a psychological examination of an unexplored phenomenon | Q39550265 | ||
| The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease | Q42689647 | ||
| Uptake of Huntington disease predictive testing in a complete population | Q45299900 | ||
| Awareness of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia Diagnoses Associated With Lower Self-Ratings of Quality of Life in Older Adults | Q47550462 | ||
| Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults | Q47742387 | ||
| Safety of disclosing amyloid status in cognitively normal older adults | Q47953945 | ||
| Return of research results: general principles and international perspectives | Q48545504 | ||
| Ethical Issues in the Development of Readiness Cohorts in Alzheimer's Disease Research | Q48547812 | ||
| Age, neuropathology, and dementia | Q48597534 | ||
| Diagnostic misconceptions? A closer look at clinical research on Alzheimer's disease | Q48604231 | ||
| Dementia in the oldest old: Beyond Alzheimer disease | Q34553751 | ||
| Varieties of uncertainty in health care: a conceptual taxonomy | Q35136761 | ||
| Public perceptions of presymptomatic testing for Alzheimer disease | Q35206422 | ||
| Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics | Q35316963 | ||
| Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials | Q35400583 | ||
| Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants | Q35595661 | ||
| Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues | Q35838385 | ||
| Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors | Q35889850 | ||
| Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease | Q36031732 | ||
| Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up | Q36420622 | ||
| The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease | Q36496436 | ||
| A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure | Q36719734 | ||
| Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study | Q36790111 | ||
| Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment | Q36883137 | ||
| Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit | Q36885357 | ||
| Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations | Q36929890 | ||
| Interventions to improve risk communication in clinical genetics: systematic review | Q37061382 | ||
| Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association | Q37069527 | ||
| Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues | Q37170455 | ||
| Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. | Q37184248 | ||
| Postgenomics, uncertain futures, and the familiarization of susceptibility genes | Q37194052 | ||
| The converged experience of risk and disease | Q37308197 | ||
| Communicating genetic risk information for common disorders in the era of genomic medicine | Q37389775 | ||
| Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. | Q37406073 | ||
| Disclosure of APOE genotype for risk of Alzheimer's disease | Q37423417 | ||
| Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease | Q37690501 | ||
| Dementia risk prediction in the population: are screening models accurate? | Q37760428 | ||
| Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease | Q38081667 | ||
| Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies | Q38287482 | ||
| Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project | Q38673458 | ||
| Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. | Q38691914 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 487-498 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals | |
| P478 | volume | 62 |
Search more.